Here are the Form 4 insider transactions from Polaryx Therapeutics, Inc. (PLYX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PLYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLYX filings page.
Polaryx Therapeutics, Inc. reported an insider-related open-market purchase of common stock. On May 27, 2026, MStone Partners Healthcare Limited bought 88,453 shares of Polaryx common stock at $4.07 per share, in a private placement that generated $360,000 in gross proceeds for the company. After this transaction, MStone held 24,233,249 shares of common stock indirectly. Polaryx CEO Alex Keun Mo Yang is the founder and Chief Executive Officer of MStone and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Polaryx Therapeutics, Inc. director and Chief Financial Officer Landis G. Michael reported an open-market purchase of common stock. On February 18, 2026, he bought 2,867 shares at an average price of $2.7871 per share, bringing his directly held stake to 228,225 shares.